REFERENCES

17. FDA, Guidelines: Manufacturing and Controls for INDs and NDAs, Pharm. Tech. Japan, 1, 1985, 835.


27. K. Ashizawa, K. Uchikawa, T. Hattori, Y. Ishibashi, T. Sato, and Y. Miyake, Pseudopolymorphism and phase stability in four solid forms of 6R 7R -7- 2 -5- amino 1 ,2, 4-thiadiazol 3 –yl- z- 2- methoxy-iminoacetamido- 3 -4 carbamoyl -1 quinuclidinioethyl 8 oxo 5 thia 1 azabicyclo 4 2 0 oct 2 ene 2 carboxylate e 1040, Journal of Pharmaceutical Sciences. 11, 893-899.


106. http://www.drugbank.ca/drugs/DB00334


